Prevencio, Inc. has announced data published in The American Journal of Cardiology, on a new proteomic blood test that determines whether a person will have a heart attack, stroke, or other major adverse cardiac event (MACE) more accurately than the currently used clinical risk factors. A total of 927 patient samples were analyzed from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study undergoing coronary angiography.
Plasma was analyzed on a panel of 109 biomarkers using the xMAP (Multi-Analyte Profiling) technology platform at Myriad RBM, including acute phase reactants, inflammatory markers, and biomarkers of atherosclerosis.
Researchers found 49 biomarkers to be associated with MACE in both a training and validation cohort. In the end, a panel of four biomarkers was determined to predict MACE without looking at clinical variables: N-terminal pro B-type natriuretic peptide (NT-proBNP), kidney injury molecule 1 (KIM-1), osteopontin, and tissue inhibitor of metalloproteinase-1 (TIMP-1).
A score was created to divide patients into low-risk and high-risk categories of having a major cardiac event within one year. With this cut-off, the negative predictive value for MACE was 97% accurate in the low-risk group and the positive predictive value for MACE was 36% for the high-risk group.
This non-invasive blood test has the potential to separate high-risk patients who need more aggressive treatment from lower-risk patients that may be able to avoid such procedures.